Fluoroquinolones: a review on anti-tubercular activity

Tuberculosis is among the most calamitous disease, leading to a high number of deaths worldwide. After the discovery of rifampicin, no new anti-tuberculosis drug has been introduced; however, USFDA approved bedaquiline and delamanid which are limited to the treatment of extensive drug resistance tuberculosis. Fluoroquinolones are already categorized as anti-tuberculosis drugs by the WHO, but Mycobacterium tuberculosis has developed resistance to fluoroquinolones. Due to the overwhelming nature of tuberculosis across the globe, urge the scientific community to develop molecules against Mycobacterium tuberculosis with improved affinity and efficacy. In this review article, we have tried to summarize the role, structure–activity relationship, and current developments of fluoroquinolone derivatives in the management of tuberculosis. The present review will provide better insights to work further in this area.